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Background:  In severe aortic stenosis (AS) treatment with Angiotensine Converting Enzyme Inhibitors (ACE-I) may be considered contraindicated 
although potentially beneficial. There is a theoretical concern that arterial vasodilatation and fixed valve obstruction might result in a severe fall in 
blood pressure (BP). There is, however, a lack of clinical randomized trials to confirm these potential risks or benefits.
Methods:  Forty-four patients with severe AS (aortic valve area <1 cm2), 32 symptomatic and 12 asymptomatic, were randomised to treatment 
with Trandolapril 2 mg daily / placebo (1:1). Patients performed a symptom limited exercise test at baseline and at day three. Measurements 
of cardiac output (CO), systemic vascular resistance (SVR) and pulmonary capillary wedge pressure (PCWP) by a Swan-Ganz catheter and left 
ventricular end-systolic volume (LVESV) by echocardiography were performed at rest and at peak exercise. Follow-up was performed until valve 
replacement or a maximum of 8 weeks where exercise echocardiography was repeated. NT-proBNP was measured at baseline and at follow-up.
Results:  At baseline exercise caused a drop in SVR from 1399±414 to 776±278 DS/cm5. ACE-I caused a drop in resting systolic BP (148±24 
to 136±24 mmHg), SVR (1358±408 to 1196±267 DS/cm5) and heart rate (72±11 to 68±10 bpm), p<0.05 for all, while CO and PCWP remained 
unchanged (5.6±1.1 to 5.6±0.9 l/min and 18±8 to 17±6 mmHg), both NS. ACE-I did not affect BP, SVR, PCWP or CO during exercise. At follow-up 
(median time: 49 days) LVESV at rest and during exercise and NT-proBNP decreased in ACE-I group (56±21 to 46±15 ml, 61±29 to 39±14 ml and 
69±79 to 50±54 pmol/L, respectively, p<0.05 for all), while these values remained unchanged in the placebo group. No adverse events due to ACE-I 
occurred during the trial and no episodes of symptomatic hypotension were noted.
Conclusion: Exercise dramatically decreases SVR in patients with severe AS, and ACE-I do not reduce SVR further during peak exercise. ACE-I does, 
however, reduce SVR at rest. A decrease in LVESV and NT-proBNP at follow-up indicates a beneficial effect of the ACE-I induced LV unloading. Finally, 
ACE-inhibition appears to be safe in patients with severe AS.
